Literature DB >> 16186402

Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes.

Shin-ichi Araki1, Masakazu Haneda, Toshiro Sugimoto, Motohide Isono, Keiji Isshiki, Atsunori Kashiwagi, Daisuke Koya.   

Abstract

To estimate the frequency of remission/regression of microalbuminuria and to identify factors affecting such outcomes in Japanese patients with type 2 diabetes, we observed 216 patients with type 2 diabetes and microalbuminuria enrolled during an initial 2-year evaluation period for the next 6 years. Remission was defined as shift to normoalbuminuria and regression as a 50% reduction in urinary albumin excretion rate (AER) from one 2-year period to the next. Reduction of urinary AER was frequent, with a 6-year cumulative incidence of 51% (95% CI 42-60) for remission and 54% (45-63) for regression, whereas the frequency of progression to overt proteinuria was 28% (19-37). Microalbuminuria of short duration, the use of renin-angiotensin system-blocking drugs, and lower tertiles for HbA(1c) (<6.95%) and systolic blood pressure (<129 mmHg) were independently associated with remission or regression in the pooled logistic regression analysis. The results indicate that reduction in urinary AER occurs frequently in Japanese patients with type 2 diabetes. Early detection of microalbuminuria and a multifactorial control may result in improved outcomes for diabetic nephropathy and cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186402     DOI: 10.2337/diabetes.54.10.2983

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  64 in total

Review 1.  Clinical impact of albuminuria in diabetic nephropathy.

Authors:  Takashi Wada; Miho Shimizu; Tadashi Toyama; Akinori Hara; Shuichi Kaneko; Kengo Furuichi
Journal:  Clin Exp Nephrol       Date:  2011-08-10       Impact factor: 2.801

2.  Polymorphisms in the 3' UTR in the neurocalcin delta gene affect mRNA stability, and confer susceptibility to diabetic nephropathy.

Authors:  Masumi Kamiyama; Masaaki Kobayashi; Shin-ichi Araki; Aritoshi Iida; Tatsuhiko Tsunoda; Koichi Kawai; Masahito Imanishi; Makoto Nomura; Tetsuya Babazono; Yasuhiko Iwamoto; Atsunori Kashiwagi; Kohei Kaku; Ryuzou Kawamori; Daniel P K Ng; Torben Hansen; Peter Gaede; Oluf Pedersen; Yusuke Nakamura; Shiro Maeda
Journal:  Hum Genet       Date:  2007-08-02       Impact factor: 4.132

3.  Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.

Authors:  Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

4.  Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes.

Authors:  S Noshad; M Mousavizadeh; M Mozafari; M Nakhjavani; A Esteghamati
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

Review 5.  Proteomic discovery of diabetic nephropathy biomarkers.

Authors:  Michael L Merchant; Jon B Klein
Journal:  Adv Chronic Kidney Dis       Date:  2010-11       Impact factor: 3.620

Review 6.  Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics.

Authors:  Julie A D Van; James W Scholey; Ana Konvalinka
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

Review 7.  Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

Authors:  George Jerums; Sianna Panagiotopoulos; Erosha Premaratne; Richard J MacIsaac
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

Review 8.  Normoalbuminuric diabetic kidney disease.

Authors:  Chao Chen; Chang Wang; Chun Hu; Yachun Han; Li Zhao; Xuejing Zhu; Li Xiao; Lin Sun
Journal:  Front Med       Date:  2017-07-18       Impact factor: 4.592

9.  Factors Associated with Microalbuminuria Remission in Patients with Type 2 Diabetes: Importance of Early Intervention for Microalbuminuric Patients (TSUGARU STUDY).

Authors:  Norio Nakamura; Ikuyo Narita; Takeshi Fujita; Reiichi Murakami; Michiko Shimada; Masayuki Nakamura; Hiroshi Osawa; Hideaki Yamabe; Ken Okumura
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 10.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.